Lexeo Stock Drops 24% Amid Friedreich Ataxia Study Results

Seeking Alpha12:03 ET

Morgan Stanley Sees $180B Patent Cliff, $380B Deal Capacity Fueling Biopharma M&A

Seeking AlphaJul 13 14:03 ET

Biogen, Eisai Get Approval for Leqembi in Israel for Treatment of Alzheimer's Disease

Biogen (BIIB) and Eisai said Friday that the Leqembi has been approved in Israel for the treatment of patients with Alzheimer's disease.The drug should be initiated in patients with mild cognitive

MT NewswiresJul 12 10:48 ET

Biogen Price Target Cut to $313.00/Share From $335.00 by Piper Sandler

Biogen Price Target Cut to $313.00/Share From $335.00 by Piper

Dow JonesJul 12 08:33 ET

Piper Sandler Maintains Overweight on Biogen, Lowers Price Target to $313

Piper Sandler analyst Christopher Raymond maintains Biogen with a Overweight and lowers the price target from $335 to $313.

Analyst UpgradesJul 12 08:23 ET

Biogen Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 07/12/2024 32.35% Piper Sandler $335 → $313 Maintains Overweight 06/28/2024 24.32% Needham $294 → $294

BenzingaJul 12 08:22 ET